Rapid

Rapid Dosimetry is a Baltimore-based healthcare technology and services company specializing in quantitative imaging and radiation dosimetry for radiopharmaceutical therapies. The company supports pharmaceutical developers, clinical researchers, and healthcare providers in the development and safe implementation of precision radiopharmaceutical treatments.

Rapid combines scientific expertise with software and consulting services to support pre-clinical and clinical studies, including those required for regulatory approval. Its capabilities span imaging protocol development, quantitative image reconstruction, centralized dosimetry, radiobiological analysis, and the preparation of detailed regulatory-ready reports.

The company's software portfolio includes 3D-RD-S, a cloud-based application designed to simplify radiopharmaceutical dosimetry. The platform calculates absorbed radiation doses and related radiobiological measures, helping researchers and clinical teams evaluate how radiopharmaceutical therapies distribute radiation throughout the body and estimate potential biological responses.

Rapid's expertise covers both alpha- and beta-emitting radiopharmaceutical therapies and incorporates imaging data from technologies such as SPECT/CT and PET/CT. Its team draws on extensive experience in nuclear medicine, medical physics, quantitative imaging, and dosimetry science to help optimize imaging protocols, assess treatment response, reduce potential toxicity to healthy organs, and support more precise treatment planning.

With a mission to simplify and standardize dosimetry for radiopharmaceutical therapy, Rapid Dosimetry is focused on advancing precision medicine in cancer treatment. By combining specialized software with expert scientific services, the company aims to make individualized radiation dosing more accessible and support the safer and more effective delivery of radiopharmaceutical therapies.